Rebel
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There must be several million short shares yet to be covered??? The last reported short interest was over 20 million (that number I believe is from mid-March, but I'm not absolutely certain of the date).
Up again in premarket by 85.8% = $.26.
Here we have another MESA stock giveaway. It's crazy. You can try to buy at the ask and wind up getting them for almost 1 cent less.
Interesting games...
Hmmm. Now up in premarket 7.91% on 11,000 shares - .15.
Up 79.86% in premarket? (400 shares at .25)
Well thank you Carnelson. I've been patiently holding since December. Things continue to be a bit sketchy, but there's real value here. You may want to subscribe to their email notification service so you don't miss anything! Because it's a pink, the news doesn't always appear in my brokerage account.
http://www.snl.com/irweblinkx/email.aspx?IID=4021224
...there are only 56.3 million in the float.
Indymac is a good example of that--it's had a few runs since the Feds took over.
Apparently, OFSI has "various non-bank" subsidiaries, one of which I think is a for-profit corporation, "Omni Community Development Corporation." I will try to find out what the others are.
CEO Klein is still holding shares that he bought in the $8-9.10 range--no sales at all over the past few years that I can find.
http://quicktake.morningstar.com/StockNet/ownership.aspx?Country=USA&Symbol=OFSI
Yes it's OFSI's subsidiary. Uh oh. What happened to the 30 days they had to come up with a plan under the Agreement signed just last week?
http://birmingham.bizjournals.com/birmingham/stories/2009/03/23/daily52.html?ana=yfcpc
Interesting comment from the Fed:
Omni...“incurred losses that have depleted most of its capital, and there is no reasonable prospect that the bank will become adequately capitalized without federal assistance.”
Is there any hope in that statement?
Nope. Shaun Bailey was appointed President of CBAY (the first time) on 1/22/08 as that article states, but CBAY Systems has nothing to do with Cal-Bay International. It's a mistake.
Hiya Timmage. Thank you very much for doing that.
Now there are 3 boardmarks!
Hmmm. Insiders are holding shares bought in the range of .80 to 2.03. As of their last filing, shareholder equity was $10.5 million, which would mean a book value of about $1.45 based on 7.2 million shares. Oh, and of their last report there were 425,500 stock options exerciseable at a weighted average price of $2.01.
Here's a link to the insider holdings scoop; if necessary, just type in EBDC.
http://insidercow.com/
Here's their last 10Q before they disappeared into pinky-land.
http://idea.sec.gov/Archives/edgar/data/1050725/000095014406010775/g04210e10qsb.htm
That's all I have time for now. Darn.
Happy Birthday, Gail! Time to celebrate...time to reflect, find your center and fill it with....CAKE!
Wishing you the very best!
Here's another low floater, OFSI. They recently signed off on an agreement with the Feds to raise their capital ratios. Shares are going for .02. Just 11.1 million outstanding/5.6 million in the float.
http://www.onb.com/
Found EBDC last week and I called them to make sure they were still in business (they are), and their website seems to be up and running. The company has been basically silent since they moved to the pinks, so for a hoot I picked up a bunch at 1 cent. I wrote to Mr. Box as well, but (surprise!!) haven't heard back yet. We'll see where this one goes. Tiny volume, tiny float (4 million).
My account is showing that there are over 20 million shares short, or 26.79% of the float.
That's a lot.
All we need is a good reason for them to start covering.
;)
Book value was $.528 as of the last quarter. The market cap is currently at $1.22 million, and my account tells me that the short interest is 26.69%. Crazy-fun stuff.
Maybe it's the suddenly quiet Bandit!
(move your bid up!)
(lol)
Thank you PCFG for the dividend! Gonna hold 'em for a while.
And don't forget the Anthrax treatment, which they're already delivering to Uncle Sam, which treatment is estimated to bring in $150 million in revenue (which amount is HIGHER than the current market cap!)
(and don't forget the 8+ million short shares)
;)
Ask .10/bid .04 = 6-cent spread on ORGG. Are they crazy? (lol)
Wow, ORGG up 566%.
Maybe I'm dreaming.
John Hancock Growth Trust in for 102,857 shares as of Friday the 13th.
http://www.mffais.com/hgsi.html
Hope it's a good sign for today. I wonder how many of the 8.49 million short shares have been covered...hmmm.
;)
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Cowen Conference 8:00 AM ET 3/13/09 | PR Newswire
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that its presentation at the Cowen and Company 29th Annual Health Care Conference will be webcast and may be accessed at www.hgsi.com.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )
A member of Human Genome Sciences' senior management team will present a corporate overview on Wednesday, March 18, 2009 from 8:45 to 9:20 am Eastern Time.
Investors interested in listening to the live webcast should log on before the start time in order to download any software required. The archive of the webcast will be available for several days after the live event.
The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.
HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. For additional information on Human Genome Sciences, Inc., visit the company's web site at www.hgsi.com.
SOURCE Human Genome Sciences, Inc.
Yup, that was on the first 8000 shares...now it's back to "normal" but still very active in premarket. I noticed that Reuters has today changed its rating on HGSI to "outperform" from "neutral."
OT (sort of) Hi Tariniterror. Yes, and picked up more in the .54-.64 range and am NOT worried.
Nice day for our PCFG for a change!
Bought today's entire volume in EBDC at 1 cent. Ebank had disappeared into pinkyland a while back. I called them the other day to make sure they were still in business..they are. 4.6 million float...we'll see. I love to buy funky stocks when no one is paying attention...wonder what you think.
If you are correct, then the market cap is a mere $811K, which seems insane when you consider the potential.
Cadillac, thanks for your technical analysis! Yes, just bought in on Tuesday at .0044, so Wednesday's jump was a pleasant surprise! A while back Reuters had this rated as "outperform," and I've been following the company ever since.
And volume is up about 7 X average 10-day. Weird and wild trading today. It will be interesting to see where it lands.
Up 260% in premarket...
It was! The analysts decided it wasn't. (lol) Wow, what a freak-out and what a bargain.
The purposes are not "unknown," but have been explained clearly by BIPH, and it makes sense. After all, there are less than 5,000 shares left in the treasury, leaving the company with little flexibility to make any forward progress. Those shares will be authorized only, and we can only hope that any shares issued will be for good reason. Insiders are shareholders too (ya know).
(hiya back, Klonopin!)
Whew. What a bad attitude. Why not let the company do what it needs to do? Micro-scrutinizing every breath they take will give you gas.
Biophan Announces Issuance of Key US Patent
7:00 AM ET 3/5/09 | Market Wire
Biophan Technologies, Inc. (OTCBB: BIPH) (FRANKFURT: BTN), a developer of next-generation medical technology, announced today that the United States Patent and Trademark Office (USPTO) issued the Company U.S. Patent No. 7,494,459, entitled "Sensor-Equipped and Algorithm Controlled Direct Mechanical Ventricular Assist Device." The patent covers important operational aspects of the Myotech Circulatory Support System (CSS) technology including critical control aspects of the drive unit.
The Myotech CSS is a novel, non-blood contacting circulatory support system consisting of a flexible polymer cup which is inserted via an incision between two ribs and is positioned around the lower half of the heart, avoiding direct contact with circulating blood, which is the primary cause of complications with competitive devices. An external drive unit actuates the CSS cup, providing active systolic and diastolic support. This design can be rapidly installed in less than five minutes. The speed of installation and lack of contact with circulating blood make the CSS a superior design for treating sudden cardiac arrest patients. Over 260,000 patients per year experience in hospital cardiac arrest in the US alone, and these patients could greatly benefit from this device.
The Company has pending application for additional patents that will cover future enhancements to the technology.
"We are excited by the issuance of this patent, which greatly increases the value of our technology portfolio," stated John Lanzafame, Biophan's CEO. "This patent is the first US patent to issue covering the Myotech CSS technology, and is an important milestone for us."
Biophan is currently seeking development and license partners to move the Myotech CSS forward into clinical trials. In addition, the Company has multiple grant applications under review at the National Institutes of Health and Department of Defense to help support research and development of the CSS technology.
About Biophan Technologies, Inc.
Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company is seeking development partners to commercialize the Myotech Circulatory Support System, which has significant potential to improve the treatment of acute heart failure. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan, please visit our website at www.biophan.com.
Second time around for Shaun Bailey, but at least he appears to be a real person. In fact, he IS the current owner of a private residence known as 5316 Hollyridge Street, North Las Vegas.
http://redrock.co.clark.nv.us/assrrealprop/pclDetail.aspx?hdnParcel=12331212031&hdnInstance=pcl7
Let's hope the check doesn't bounce.
Ah, but the bid has moved up to .0045 as of 8:49 this morning, which is mildly interesting.
;)
Who knows. My account is showing a 60.9 million float with 31% short.
I don’t think so. It’s my understanding that they simply re-named the MBI Illinois division and transferred their $537 billion bond portfolio to this new entity, such that National Public Finance Guaranty Corp. will be a separate corporation, but still a subsidiary of MBI.
Yes indeed. Jay Brown is a smart guy, making smart moves under strange, unprecedented circumstances. Mr. Freaky-Jittery Market seems to like it too!
;)
MBIA creates separate public finance bond insurance company 7:25 AM ET 2/18/09 | Marketwatch
NEW YORK (MarketWatch) -- MBIA Inc. said Wednesday it is creating a new public-finance financial guarantee insurance company through a restructuring of its main insurance subsidiary, MBIA Insurance Corp. Under the move, MBIA Insurance Corp. of Illinois will be renamed National Public Finance Guarantee Corporation, which MBIA Chief Executive Jay Brown said will be "dedicated exclusively to the U.S. public finance market." As part of the deal, MBIA Corp. has ceded to the National entity all of MBIA Corp.'s U.S. public finance business and paid to National approximately $2.89 billion as a premium to reinsure the policies covered by the reinsurance and assignment agreements, with MBIA Corp. receiving a 22% "ceding commission" on the unearned premium reserve. In a letter released with the announcement, CEO Brown said new unit is not part of a "good bank/bad bank split" and will be capitalized above the level required for a AAA credit rating. He added: "While some market participants have chosen to focus on our recent downgrades and have suggested that our prospects were nonexistent, that could not be further from the truth. Our embedded adjusted book value is still over $40 per share."